Treatment of elderly patients with stage IV non-small-cell lung cancer

References

• Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin.61, 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol.24, 4539–4544 (2006).
   PubMed Web of Science ®Google Scholar
• Yang P, Allen MS, Aubry MC et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest128, 452–462 (2005).
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J. Clin. Oncol.25, 5570–5577 (2007).
   PubMed Web of Science ®Google Scholar
• Yee KW, Pater JL, Pho L et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J. Clin. Oncol.21, 1618–1623 (2003).
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med.341, 2061–2067 (1999).
   PubMed Web of Science ®Google Scholar
• Jatoi A, Hillman S, Stella P et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J. Clin. Oncol.23, 9113–9119 (2005).
   PubMed Web of Science ®Google Scholar
• Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl Cancer Inst.91, 66–72 (1999).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl Cancer Inst.95, 362–372 (2003).
   PubMed Web of Science ®Google Scholar
• Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J. Clin. Oncol.18, 2529–2536 (2000).
   PubMed Web of Science ®Google Scholar
• Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J. Clin. Oncol.24, 3657–3663 (2006).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guideline: Update 2003. J. Clin. Oncol.22, 330–353 (2004).
   PubMed Web of Science ®Google Scholar
• Pallis AG, Gridelli C, van Meerbeeck JP et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann. Oncol.21, 692–706 (2010).
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, Phase 3 trial. Lancet378(9796), 1079–1088 (2011).
   PubMed Web of Science ®Google Scholar
• Abe T, Yokoyama A, Takeda K et al. Randomized Phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): an intergroup trial of JCOG0803/WJOG4307L. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 7509).
   Google Scholar
• Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl Cancer Inst.94, 173–181 (2002).
   PubMed Web of Science ®Google Scholar
• Belani CP, Fossella F. Elderly subgroup analysis of a randomized Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer104, 2766–2774 (2005).
   PubMed Web of Science ®Google Scholar
• Ansari RH, Socinski MA, Edelman MJ et al. A retrospective analysis of outcomes by age in a three-arm Phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit. Rev. Oncol. Hematol.78, 162–171 (2011).
   PubMedGoogle Scholar
• Davidoff AJ, Tang M, Seal B et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J. Clin. Oncol.28, 2191–2197 (2010).
   PubMed Web of Science ®Google Scholar
• Chrischilles EA, Pendergast JF, Kahn KL et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J. Clin. Oncol.28, 620–627 (2010).
   PubMedGoogle Scholar
• Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361, 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol.11, 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362, 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G et al. Efficacy results from the randomised Phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations. Ann. Oncol.21, viii 6 (2010) (Abstract LBA13).
   Google Scholar
• Rosell R, Gervais R, Vergnenegre A et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) Phase III randomized trial. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 7503).
   PubMedGoogle Scholar
• Crino L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, Phase II study. J. Clin. Oncol.26, 4253–4260 (2008).
   PubMed Web of Science ®Google Scholar
• Stinchcombe T, Peterman A, Lee CB et al. A randomized Phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age >=70 years) with stage IIIB/IV non-small cell lung cancer. J. Thorac. Oncol.6(9), 1569–1577 (2011).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAiL). Ann. Oncol.21, 1804–1809 (2010).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J. Clin. Oncol.26, 60–65 (2008).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol.27, 1227–1234 (2009).
   PubMed Web of Science ®Google Scholar
• Leighl NB, Zatloukal P, Mezger J et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the Phase III BO17704 study (AVAiL). J. Thorac. Oncol.5, 1970–1976 (2010).
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet372, 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353, 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18, 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol.18, 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase 3 study. Lancet374, 1432–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol.11, 521–529 (2010).
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized Phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol.24, 4405–4411 (2006).
   PubMed Web of Science ®Google Scholar
• Wheatley-Price P, Ding K, Seymour L et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.26, 2350–2357 (2008).
   PubMed Web of Science ®Google Scholar
• Hurria A, Cirrincione CT, Muss HB et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J. Clin. Oncol.29, 1290–1296 (2011).
   PubMed Web of Science ®Google Scholar
• Luciani A, Ascione G, Bertuzzi C et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J. Clin. Oncol.28, 2046–2050 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen HJ, Feussner JR, Weinberger M et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N. Engl. J. Med.346, 905–912 (2002).
   PubMed Web of Science ®Google Scholar
• Stuck AE, Siu AL, Wieland GD et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet342, 1032–1036 (1993).
   PubMed Web of Science ®Google Scholar
• Tinetti ME, Baker DI, McAvay G et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N. Engl. J. Med.331, 821–827 (1994).
   PubMed Web of Science ®Google Scholar
• Inouye SK, Brown CJ, Tinetti ME. Medicare nonpayment, hospital falls, and unintended consequences. N. Engl. J. Med.360, 2390–2393 (2009).
   PubMed Web of Science ®Google Scholar
• Hiyama K, Hiyama E, Ishioka S et al. Telomerase activity in small-cell and non-small-cell lung cancers. J. Natl Cancer Inst.87, 895–902 (1995).
   PubMedGoogle Scholar
• Liu Y, Sanoff HK, Cho H et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell8, 439–448 (2009).
   PubMed Web of Science ®Google Scholar
• Liu Y, Johnson SM, Fedoriw Y et al. Expression of p16INK4a prevents cancer and promotes aging in lymphocytes. Blood117, 3257–3267 (2011).
   PubMedGoogle Scholar
• Muss HB, Krishnamurthy J, Alston SM et al. P16INK4a expression after chemotherapy in older women with early-stage breast cancer. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 9002).
   Google Scholar
• Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis.41, 1–12 (2003).
   PubMed Web of Science ®Google Scholar
• Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat. Rev.21, 33–64 (1995).
   PubMed Web of Science ®Google Scholar
• Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J. Clin. Oncol.18, 2780–2787 (2000).
   PubMed Web of Science ®Google Scholar
• Mita AC, Sweeney CJ, Baker SD et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J. Clin. Oncol.24, 552–562 (2006).
   PubMed Web of Science ®Google Scholar
• Swedko PJ, Clark HD, Paramsothy K et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch. Intern. Med.163, 356–360 (2003).
   PubMed Web of Science ®Google Scholar
• Weiss J, Eaby B, Stevenson J et al. Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience. J. Thorac. Oncol.5, 667–672 (2010).
   PubMedGoogle Scholar
• Raisz LG. Clinical practice. Screening for osteoporosis. N. Engl. J. Med.353, 164–171 (2005).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol.21, 3150–3157 (2003).
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol.28, 5132–5139 (2010).
   PubMed Web of Science ®Google Scholar
• Jorgensen TL, Hallas J, Herrstedt J. Polypharmacy in elderly cancer patients. J. Clin. Oncol.28(Suppl.), (2010) (Abstract 9074).
   PubMedGoogle Scholar
• Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist12, 1070–1083 (2007).
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol.27, 6251–6266 (2009).
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Giaccone G, Temin S. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Oncol. Pract.6, 39–43 (2010).
   PubMedGoogle Scholar
• D’Addario G, Fruh M, Reck M et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v116–v119 (2010).
   PubMed Web of Science ®Google Scholar
• de Marinis F, Rossi A, Di Maio M et al. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer73, 1–10 (2011).
   PubMed Web of Science ®Google Scholar